Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Immuno-Oncology Congress 2023

Co-formulation bispecific approaches

Teclistamab as a challenge to CAR T

Date

07 Dec 2023

Session

Co-formulation bispecific approaches

Topics

Immunotherapy

Tumour Site

Multiple Myeloma

Presenters

Tobias Kampfenkel

Authors

T. Kampfenkel

Author affiliations

  • Witten/DE

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Anti-DLL3 x CD3 BiTe

Presenter: Gregory Friberg

Session: Co-formulation bispecific approaches

Resources:

Slides

Webcast

Q&A and discussion

Presenter: All Speakers

Session: Co-formulation bispecific approaches

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.